BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28556956)

  • 21. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
    Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
    JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors.
    Cleary SP; Gryfe R; Guindi M; Greig P; Smith L; Mackenzie R; Strasberg S; Hanna S; Taylor B; Langer B; Gallinger S
    J Am Coll Surg; 2004 May; 198(5):722-31. PubMed ID: 15110805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer.
    van der Zee JA; van Eijck CH; Hop WC; van Dekken H; Dicheva BM; Seynhaeve AL; Koning GA; Eggermont AM; Ten Hagen TL
    Eur J Surg Oncol; 2012 Nov; 38(11):1058-64. PubMed ID: 22633450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
    Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
    Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer.
    Matsubayashi H; Infante JR; Winter J; Klein AP; Schulick R; Hruban R; Visvanathan K; Goggins M
    Cancer Biol Ther; 2007 Oct; 6(10):1569-75. PubMed ID: 18000398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation.
    Siu MK; Kong DS; Ngai SY; Chan HY; Jiang L; Wong ES; Liu SS; Chan KK; Ngan HY; Cheung AN
    PLoS One; 2015; 10(7):e0133467. PubMed ID: 26218748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
    Robinson SM; Rahman A; Haugk B; French JJ; Manas DM; Jaques BC; Charnley RM; White SA
    Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease.
    Pai RK; Beck AH; Mitchem J; Linehan DC; Chang DT; Norton JA; Pai RK
    Am J Surg Pathol; 2011 Feb; 35(2):228-34. PubMed ID: 21263243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Pancreatic Fistula on Recurrence and Long-Term Prognosis of Periampullary Adenocarcinomas after Pancreaticoduodenectomy.
    Serrano PE; Kim D; Kim PT; Greig PD; Moulton CA; Gallinger S; Wei AC; Cleary SP
    Am Surg; 2016 Dec; 82(12):1187-1195. PubMed ID: 28234183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
    Chang DT; Chapman CH; Norton JA; Visser B; Fisher GA; Kunz P; Ford JM; Koong AC; Pai RK
    Cancer; 2010 Nov; 116(22):5179-87. PubMed ID: 20665497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p21-Activated kinase 4 predicts early recurrence and poor survival in patients with nonmetastatic clear cell renal cell carcinoma.
    Liu W; Yang Y; Liu Y; Liu H; Zhang W; Xu L; Zhu Y; Xu J
    Urol Oncol; 2015 May; 33(5):205.e13-21. PubMed ID: 25744653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions.
    Duxbury MS; Matros E; Clancy T; Bailey G; Doff M; Zinner MJ; Ashley SW; Maitra A; Redston M; Whang EE
    Ann Surg; 2005 Mar; 241(3):491-6. PubMed ID: 15729073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
    Kimura K; Amano R; Nakata B; Yamazoe S; Hirata K; Murata A; Miura K; Nishio K; Hirakawa T; Ohira M; Hirakawa K
    World J Surg Oncol; 2014 Nov; 12():360. PubMed ID: 25429841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations.
    Kim JH; Park SH; Yu ES; Kim MH; Kim J; Byun JH; Lee SS; Hwang HJ; Hwang JY; Lee SS; Lee MG
    Radiology; 2010 Oct; 257(1):87-96. PubMed ID: 20697118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resectable pancreatic adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting pathology and patient outcomes.
    Cassinotto C; Chong J; Zogopoulos G; Reinhold C; Chiche L; Lafourcade JP; Cuggia A; Terrebonne E; Dohan A; Gallix B
    Eur J Radiol; 2017 May; 90():152-158. PubMed ID: 28583627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
    Pietrasz D; Pécuchet N; Garlan F; Didelot A; Dubreuil O; Doat S; Imbert-Bismut F; Karoui M; Vaillant JC; Taly V; Laurent-Puig P; Bachet JB
    Clin Cancer Res; 2017 Jan; 23(1):116-123. PubMed ID: 27993964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma.
    Lu CD; Morita S; Ishibashi T; Hara H; Isozaki H; Tanigawa N
    Cancer; 1999 Mar; 85(6):1250-60. PubMed ID: 10189129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
    Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
    Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreas.
    Meszoely IM; Lee JS; Watson JC; Meyers M; Wang H; Hoffman JP
    Am Surg; 2004 Mar; 70(3):208-13; discussion 213-4. PubMed ID: 15055843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.